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Abstract 
A single astrocyte can ensheath more than 100,000 synapses within its domain. Thus, 
astrocytes are ideally positioned to integrate signals from a few synapses to have impact on 
all ensheathed synapses with high efficiency. As neuromodulators are released in a volume 
manner and are known to ellicit astrocyte calcium responses, we hypothesized that 
astrocytes may be effector cells, extending neuromodulator action to every synapse. Using 
live mouse brain slices, extracellular recordings of evoked excitatory postsynaptic 
potentials (eEPSPs), and select pharmacology, we assessed the astrocytic involvement in 
paired-pulse suppression and serotonin-mediated shaping of a simple sensory cortical 
network containing both excitatory and inhibitory activity. 
Using a paired-pulse stimulus repeated every 20 seconds, we assessed the role of 
astrocytes in paired-pulse suppression by applying pharmacological agents in the bath 
perfusate to interfere with astrocyte function. We then applied them in the presence of the 
GABAA antagonist bicuculline to determine if effects were dependent on GABA. To assess 
the role of astrocytes in serotonin neuromodulation, serotonin was administered as a bolus 
to the bath perfusate upstream of the recording site to simulate transient effects on the 
network. Serotonin was applied both before and after bath application of pharmacological 
agents considered to affect astrocyte function or signaling mechanisms. 
In the absence of neuromodulators or pharmacological agents, the first cortical eEPSP is 
much larger in amplitude than the second due to the recruitment of longer -lasting 
inhibitory activity resulting from the first stimulus. Pharmacological disruption of 1) 
astrocytic mGluR5 receptors, 2) astrocyte metabolism, 3) gap junctions/hemichannels, or 
4) purinergic receptors resulted in a significant loss of this evoked inhibition in field 
recordings, suggesting that astrocytes may play a role in tonic aspects of network 
inhibition. Furthermore, all significance was lost when performed in the presence of 
bicuculline, suggesting that astrocytic involvement in paired-pulse suppression is GABAA 
dependent. In addition to effects seen on tonic cortical inhibition, serotonin effects on 
frequency transmission in the cortical network are significantly altered following 
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pharmacological astrocyte disruption. Lastly, serotonin-mediated frequency transmission 
could also be disrupted using P2 antagonists suggesting that ATP signaling (astrocyte 
currency) may be involved. 
These data highlight a potential role for astrocytes in cortical inhibitory activity seen in 
this sensory cortical network and that serotonin acts on astrocytes to partially exert its 
modulatory influence.  
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1.0 Introduction  
Astrocytes are the most abundant cell type in the brain and play important roles in ion 
homeostasis, metabolism, neurotransmitter clearance, synapse formation/removal, 
neurovascular coupling, and modulating neurotransmission. They are instrumental in 
metabolic processes as they respond accordingly to the activity dependent needs of 
neurons through the astrocyte-neuron lactate shuttle (Pellerin et al., 2007). Lactate is the 
oxidative substrate preferred by neurons. During neuronal activation, glutamate increases 
lactate consumption by neurons. Glutamate also increases glycolysis in astrocytes to 
provide neurons with lactate in order to maintain neurotransmission (Pellerin et al., 2007). 
Astrocytes also maintain a role in modulation of cerebral blood flow (Gordon et al., 2008). 
Blood vessels are covered by astrocyte end feet which regulate vasoconstriction and 
vasodilation of arterioles. Calcium signaling in astrocytes is coupled to changes in neural 
activity, which produces changes in blood flow. As oxygen availability is typically low in the 
brain (near the hypoxic threshold), astrocyte calcium increases lead to astrocyte lactate 
release and resulting vasodilation (Gordon et al., 2008).  
Astrocytes are responsible for rapidly clearing the extracellular space. Of particular 
importance is the clearance of glutamate to prevent excitotoxicity during 
neurotransmission.  This is required in order for neurons to survive and function normally 
(Anderson and Swanson, 2000). In addition to clearing glutamate, astrocytes also release 
glutamate as a gliotransmitter to contribute to the regulation of neural activity at the 
synapse (Anderson and Swanson, 2000). Furthermore, astrocytes play an important role in 
potassium homeostasis. During neuronal activity, potassium re-uptake by neurons is too 
slow to prevent potassium accumulation. A buildup of extracellular potassium would affect 
proper transmission and channel kinetics. Astrocytes compensate for this via three 
mechanisms; carrier operated potassium-chloride uptake, channel operated potassium 
chloride uptake, and they act as an interconnected (gap junctions) spatial buffer that 
effectively sequesters excess potassium away from neurons (Walz, 2000).  
 2 
Astrocytes are thought to form a tripartite synapse with pre- and post-synaptic neurons. 
They envelope the synapse and can respond to activity at excitatory (glutamate) and 
inhibitory (GABA) synapses as well as possess cholinergic, adrenergic, and peptidergic 
receptors (Hosli and Hosli, 2000). Upon substrate-receptor activation, alterations in 
astrocyte calcium propagate from astrocyte to astrocyte in a syncytium that can widely 
affect brain function. This leads to the release of gliotransmitters, such as ATP, D-serine, 
and/or glutamate (Bezzi and Volterra, 2001). Therefore, it is possible that astrocytes 
modulate neuronal activity at many synapses across great distance. 
1.1 Astrocytes are well positioned to modulate neurotransmission 
20-40% of the total number of cells in the brain are astrocytes (Herculano-Houzel, 
2014). They establish distinct territories that do not overlap except at narrow bands of 
profuse interdigitation between fine processes at their domain boundaries (Fig 1.1A) 
(Bushong et al., 2002). Astrocytes do not intermingle with each other but they profusely 
interweave their processes with other glial cell processes (Bushong et al., 2002). In 
addition, it is thought that astrocytes form a tripartite synapse with neurons in which the 
 3 
astrocyte wraps around the synaptic connection between pre- and post-synaptic neurons 
(Fig 1.1B)  (Araque et al., 1999a, Grosche et al., 1999, Ventura and Harris, 1999).  As a 
single astrocyte can make connections with up to 140,000 synapses in its domain (Bushong 
et al., 2002), this puts them in an ideal position to integrate neuronal inputs and modulate 
synaptic activity. 
1.2 Astrocytes in neurotransmission 
Astrocytes were originally thought to play merely a structural role in the brain. 
However, recent evidence now supports that they play a role in modulating neuronal 
activity (Araque et al., 1999a, Allen and Barres, 2005, Panatier et al., 2011). As it is thought 
that astrocytes wrap around every synapse to form the tripartite synapse  (Fig 1.1B) 
(Araque et al., 1999a, Grosche et al., 1999, Ventura and Harris, 1999), this would enable 
them to respond to neurotransmitter release (such as glutamate) at the synapse and 
respond accordingly to modulate wide brain function (Araque et al., 1998).  They have been 
shown to possess receptors for various neurotransmitters such as acetylcholine, 
norepinephrine, serotonin, and glutamate among others (Hosli and Hosli, 2000). In 
particular the mGluR5 glutamate receptor can be activated to induce intracellular calcium 
elevations (Nakahara et al., 1997, Panatier and Robitaille, 2016), which is a crucial function 
of astrocyte signaling. 
Metabotropic glutamate receptors are present on both glial cells and neurons. There 
are eight metabotropic glutamate receptors, which are classified into three groups. Group I 
includes mGluR1 and mGluR5 and are coupled to Gq G-proteins that activate phospholipase 
C (PLC) and generally modulate excitation. Group II consists of mGluR2 and mGluR3, while 
Group III includes mGluR4, mGluR6, mGluR7, and mGluR8. Group II and III are negatively 
coupled to adenylate cyclase through Gi/o and are predominantly located pre-synaptically 
to  generally decrease excitability (Gereau and Swanson, 2008, Sherman, 2014). 
It has been shown that in response to elevated calcium, astrocytes release 
gliotransmitters, such as ATP (Bowser and Khakh, 2004).  The tripartite synapse marks 
astrocytes as ideal candidates to modulate neuronal activity as they can respond to 
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synaptic activity accordingly, via calcium waves and gliotransmitter release, to regulate 
neurotransmission. 
1.2.1 Astrocyte Calcium Signaling  
Communication among astrocytes is achieved through calcium waves which are 
induced by transmitters released from neurons at the synapse (Dani et al., 1992). For 
example, glutamate has been shown to induce calcium oscillations in astrocytes (Cornell-
Bell et al., 1990, Cornell-Bell and Finkbeiner, 1991, Porter and McCarthy, 1996). These 
glutamate-stimulated calcium elevations spread from one astrocyte to another which forms 
a long-range signaling pathway to affect extensive brain function (Cornell-Bell et al., 1990). 
It has been shown that astrocytes are connected at the border between domains where 
their fine processes interact through gap junctions (Finkbeiner, 1992). Calcium levels are 
thought to be increased via the second messenger, inositol triphosphate (IP3), which is 
spread through these gap junctions. This results in a subsequent calcium increase in 
neighboring astrocytes (Charles et al., 1992, Leybaert et al., 1998). However, this passive 
diffusion is not sufficient to propagate the spread of calcium waves great distances. In 
addition, studies have shown that the intracellular calcium increase can jump between two 
groups of astrocytes that are not connected by gap junctions (Sneyd et al., 1994). Thus, 
there must be an extracellular mechanism by which calcium waves are regenerated and 
propagated. A likely mechanism is the release of gliotransmitters, particularly ATP (Stout et 
al., 2002, Guthrie et al., 1999), which can act on adjacent astrocyte to regenerate the 
calcium wave (Anderson et al., 2004). Therefore, astrocytes propagate calcium signals 
across short distances via diffusion of IP3 through gap junctions to elevate intracellular 
calcium in connected astrocytes and across longer distances via gliotransmitter release that 
would act on neighboring astrocytes not connected through gap junctions (Fig 1.2).  
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1.2.2 ATP is astrocyte currency 
Increases in astrocyte intracellular calcium can trigger the release of the 
gliotransmitters, ATP, D-serine, and glutamate (Bezzi and Volterra, 2001). These 
gliotransmitters have been shown to act on neurons to regulate transmission (Parpura et 
al., 1994, Pasti et al., 1997, Araque et al., 1999b, Perea et al., 2009, Panatier et al., 2011) . 
Moreover, evidence has been provided to support that astrocytes release ATP in response 
to elevated calcium. Astrocytes express PAR-1 receptors that can be activated by TFLLR to 
induce rises in calcium and gliotransmitter release (Debeir et al., 1997, Junge et al., 2004, 
Lalo et al., 2014). The ATP released can then act to induce further ATP release, which 
maintains and propagates calcium waves throughout the syncytium (Coco et al., 2002, 
Anderson et al., 2004, Guthrie et al., 1999).  In addition to propagating calcium waves, ATP 
released from astrocytes can act to modulate synaptic activity though its actions on 
purinergic receptors on, neurons, interneurons, and neighboring astrocytes (Khakh et al., 
2003, Koizumi et al., 2003, Zhang et al., 2003, Anderson et al., 2004, Lalo  et al., 2014).  
These actions are excitatory or inhibitory and ATP can either be the sole transmitter or a 
co-transmitter to modulate synaptic activity (Abbracchio et al., 2009). Various purinergic 
receptor subtypes have been indicated to be widely distributed throughout the brain 
(Guthrie et al., 1999). This is significant as studies have demonstrated that high 
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concentrations of nucleotides are present in pathological states of the CNS (Abbracchio et 
al., 2009). For example, immediately after a traumatic insult, astrocytes respond by 
releasing ATP to activate microglia to form a protective barrier (Abbracchio et al., 2009). 
ATP can act directly or it can induce effects through the action of its metabolites when it is 
degraded. 
1.2.3 ATP uptake and release 
ATP is taken up by astrocytes via the chloride dependent vesicular  nucleotide 
transporter (VNUT). This transporter is highly expressed in chromaffin gr anules and 
astrocytes (Sawada et al., 2008).  However, the mechanism of ATP release is highly debated 
and there is evidence to support multiple methods including; vesicular release, ATP-
binding cassette transporters, connexon or pannexin hemichannel gap junctions, and 
voltage-dependent anion channels which include P2X receptors (Abbracchio et al., 2009). 
The two mechanisms most highly debated between these are ATP release by exocytosis 
and ATP release through hemichannel gap junctions. For example, Haydon and colleagues 
have provided evidence to support the release of ATP by vesicular release from astrocytes. 
They used the transgenic dn-SNARE mouse model in addition to various manipulations of 
exocytosis (Lalo et al., 2014). However, other studies have shown that ATP can be released 
through hemichannels (Stout et al., 2002, Garré et al., 2010, Wei et al., 2014). In addition, 
one study suggested that ATP is initially released via exocytosis, which then modulates 
further release of ATP through hemichannels (Garré et al., 2010). ATP release is thought to 
be calcium dependent. However, some studies have shown ATP release in the absence of 
calcium demonstrating that there can be multiple ATP release pathways with varying 
dependence on calcium (Queiroz et al., 1999, Coco et al., 2002). 
1.2.4 ATP metabolism 
After ATP is released, ectonucleotidase enzymes rapidly degrade it (Fig 1.3). ATP is 
metabolized into ADP, AMP, and finally adenosine which can also act as ligands for 
purinergic receptors (Abbracchio et al., 2009). The ectonucleotidases that breakdown ATP 
include the ectonucleoside triphosphate diphosphohydrolases (E-NTPDs), the 
ectonucleotide pyrophosphatase/phosphodiesterases (E-NPPs), alkaline phosphatases, and 
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ecto-5’-nucleotidases. E-NTPDs and E-NPPs hydrolyze ATP and ADP to AMP which is then 
hydrolyzed by ecto-5’-ectonucleotidase into adenosine.  In 
addition, alkaline phosphatase equally hydrolyzes ATP, ADP, 
and AMP (Fig 1.3) (Zimmermann et al., 1998, Zimmermann, 
2006). All products of ATP metabolism, including ADP, AMP 
and adenosine further act on their respective purinergic 
receptors to produce various effects. ATP therefore has the 
capability to mediate effects at multiple levels.  
1.2.5 ATP receptors 
Purinergic receptors are widely distributed throughout the brain.  ATP plays a 
unique role in glial-neuron and glial-glial interactions as all types of functional glia express 
purinergic receptors. There are two groups of purinergic receptors, P1 and P2. Adenosine 
acts on P1 purinergic receptors, while ATP acts on the P2 purinergic receptors (Abbracchio 
et al., 2009).  
P1 receptors for adenosine include the A1, A2a, A2b and A3 receptors which are 
coupled to G-proteins. A1 and A3 are coupled to Gi/o, while A2 receptors are coupled to Gs 
(Abbracchio et al., 2009). The actions of adenosine can often be either antagonistic or 
synergistic to those of ATP (Abbracchio et al., 2009), and have frequently been shown to be 
involved in many neuropathologies ranging from epilepsy and neurodegenerative 
disorders to psychiatric conditions (Boison, 2008).  
P2 purinergic receptors are further divided into two subgroups, metabotropic P2Y 
receptors and ionotropic P2X receptors (Abbracchio et al., 2009). There are seven P2X 
receptor subtypes, P2X1-7, which are cationic ligand operated channels that become 
permeable to sodium, potassium, and calcium upon binding of ATP (Khakh, 2001). 
Postsynaptic P2X receptors interact with various ionotropic receptors to have a reciprocal 
inhibitory effect, which is mediated through intracellular calcium to cause phosphorylation. 
The receptors that postsynaptic P2X receptors interact with include nicotinic acetylcholine 
receptors, A type gamma-Aminobutyric acid (GABAA), and N-methyl-D-aspartate (NMDA) 
receptors (Khakh et al., 2000). There are eight P2Y receptor subtypes, P2Y1, P2Y2, P2Y4, 
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P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14, which are coupled to either Gq/11 or Gi/o to activate the 
PLC pathway or inhibit cAMP respectively (Abbracchio et al., 2006).  Extracellular ATP has 
been shown to induce intracellular ATP release from astrocytes through its action on both 
astrocytic P2X and P2Y receptors (Anderson et al., 2004).  
1.2.6 ATP acts on interneurons 
It is possible that ATP released from astrocytes acts on interneurons to contribute to 
the modulation of GABA release and in turn, inhibition. Bowser and Khakh showed that 
stratum radiatum interneurons are excited by ATP and consequently release GABA onto 
their postsynaptic targets. ATP increased inhibition of output pyramidal neurons by 
increasing the frequency of IPSCs and triggering IPSCs of larger conductance (Bowser and 
Khakh, 2004). These effects are in part mediated through P2Y receptors on interneurons as 
opposed to P2X or P1 receptors. No staining for purinergic receptors was seen in CA1 
pyramidal neurons which was consistent with the lack of ATP evoked currents that was 
observed in these cells. However, interneurons were immunopositive for P2Y receptors 
further implicating them in modulation of inhibition. In addition, they found that 
interneurons expressing P2Y receptors were profusely surrounded by astrocytes with 
highly branched morphologies suggesting that they might be the source of ATP (Bowser 
and Khakh, 2004). 
1.2.7 Glutamate can elicit calcium waves in astrocytes and ATP release 
Astrocytes express receptors for glutamate, acetylcholine, norepinephrine, 
serotonin, and ATP (Haydon, 2001). The triggering stimulus for astrocytes involves 
vesicular release of glutamate from presynaptic nerve terminals (Bowser and Khakh, 
2004). It is thought that glutamate acts on astrocytes at the synaptic nerve terminal and 
astrocytes release ATP at more distant sites to propagate the signal through the syncytium 
(Bowser and Khakh, 2004). It is possible that other transmitters, through their alteration of 
calcium in astrocytes, can alter this mechanism. Serotonin may be one such transmitter.  
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1.3 Serotonin 
1.3.1 Serotonin neuromodulatory projection and anatomy 
Serotonin neurons originate in the midbrain raphe nuclei and project extensively 
throughout the cortex (Fig 1.4). Serotonergic axons are present in all areas of the cortex 
and all cortical layers receive some serotonin afferents. Each area has a characteristic 
pattern of serotonin innervation (Wilson and Molliver, 1991). Bundles of large diameter 
axons are observed in successive sections as they ascend through the midbrain tegmentum, 
medial forebrain bundle, diagonal band, and supracallosal stria on their way to the cortex. 
The large diameter of these axons suggests 
that they are fibers of passage and once 
they reach the cortex, the serotonergic 
axons develop a distinct morphology of 
fine, densely branched plexuses that are 
extremely convoluted (Lidov et al., 1980). 
The density of serotonergic axons tends to 
be higher in sensory areas than in motor 
areas, but is substantially higher than 
noradrenergic and dopaminergic fibers 
throughout the cortex (Lidov et al., 1980).  
1.3.2 Serotonin receptors, release, and metabolism 
All cells in the brain are directly or indirectly influenced by serotonin. There is a 
growing body of evidence to support that there are several subsystems of serotonin that 
serve different functions. However, the ability of all subsystems to produce, take up, store, 
and release serotonin is similar and they all require the same biosynthetic and transport 
mechanisms (Gaspar and Lillesaar, 2012).  
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Serotonin is synthesized from tryptophan. 
Tryptophan is first converted to 5-hydroxytryptophan 
(5-HTP) by the enzyme tryptophan hydroxylase (TPH). 
A decarboxylase enzyme then converts 5-HTP into the 
active serotonin molecule, 5-hydroxytrypamine (5-HT) 
(Fig 1.5) (Gutknecht et al., 2009). After biosynthesis 5-
HT is concentrated in the synaptic vesicles in neurons by 
the transporter, vesicular monoamine transporter 
(VMAT) (Abbracchio et al., 2006). To maintain 
homeostasis, 5-HT it is degraded by monoamine oxidase 
enzymes (MAOs) after its release. MAO-A is the main 
variant responsible for 5-HT metabolism in the CNS. MAO-A metabolizes 5-HT into 5-
hydroxyindole acetaldehyde which is then further degraded to 5-hydroxyindole acetic acid 
(5-HIAA) (Fig 1.5) (Shih et al., 2011).  
There are numerous types of serotonin receptors that have various mechanisms and 
effects. For example, some serotonin receptors act via adenylate cyclase and have 
inhibitory effects while others act via the phosphatidyl inositol second messenger system 
and have excitatory effects (Wilson and Molliver, 1991).There are thought to be as many as 
13 different G-protein coupled receptors and one family of ligand gated ion channels. 
Serotonin receptors are subdivided into seven different groups (5-HT1 to 5-HT7) based on 
their structure and function. The 5-HT1 receptor group consists of 5-HT1A, 5-HT1B, 5-HT1D, 
5-HT1E and 5-HT1F and are primarily autoreceptors that preferentially couple to G i/o to 
inhibit cAMP formation to regulate the release of neurotransmitters. The 5-HT2 receptor 
group includes 5-HT2A, 5-HT2B and 5-HT2C receptors that preferentially couple to Gq/11 to 
increase intracellular calcium via the IP3 pathway. 5-HT3 receptors are ligand gated ion 
channels similar to those for acetylcholine and GABA. 5-HT4,6,7 receptors couple to Gs to 
promote cAMP. One study by Carson and coworkers suggested that 5-HT5 receptors might 
be predominantly expressed in astrocytes and negatively coupled to adenylate cyclase 
(Carson et al., 1996). However, their function and mechanism remains unclear and there is 
little evidence to confirm that they are endogenously expressed (Hoyer et al., 2002). Many 
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serotonin receptor subtypes are expressed on both astrocytes and neurons throughout the 
brain (Shimizu et al., 1997, Hirst et al., 1998, Zhang et al., 2010). This wide variety and 
distribution of receptor types allows for a vast array of signaling actions.  
1.3.3 Serotonin effects on spontaneous and evoked EPSP/IPSP amplitudes and 
frequency in the cortex 
Serotonin neurotransmission is implicated in a vast array of behavioral and 
physiological states and functions including mood, sleep, anxiety, among many others 
(Jacobs and Azmitia, 1992).  It can induce a facilitation effect in response to excitatory 
amino acids glutamate, NMDA, and quisqualate (Nedergaard et al., 1987), and it also has 
possible effects on GABAergic interneurons (Sheldon and Aghajanian, 1990). It can 
facilitate GABA release via activation of 5-HT2A receptors, which increases interneuron 
excitability via inhibition of TASK-3 potassium channels. This leads to membrane 
depolarization and resulting increase in action potential firing (Deng and Lei, 2008). 
Serotonin effects can be postsynaptic as its receptors are distributed over large areas of the 
cell membrane (Nedergaard et al., 1987). Therefore, depending on the receptor type and 
location serotonin can exert wide range of inhibitory or excitatory effects in different 
neural networks. 
1.3.4 Astrocytic recruitment of interneurons 
It has been suggested that neuronal activity and glutamate release can trigger 
calcium elevations in astrocyte networks (Dani et al., 1992, Porter and McCarthy, 1996).  
Glutamate levels reach excess during neuronal release, which results in some of it escaping 
the synaptic cleft. This excess has been shown to reach sufficient concentrations to bind 
and activate receptors on astrocytes (Dzubay and Jahr, 1999). The glutamate receptor 
mGluR5 is found on astrocytes and is coupled to Gq and G11 G-protein variants that, when 
activated, result in stimulation of the IP3 pathway, leading to mobilization of intracellular 
astrocyte calcium (Nakahara et al., 1997, Pasti et al., 1997, Panatier and Robitaille, 2016). 
In response to elevated calcium, astrocytes release ATP, which acts on interneurons to 
modulate inhibition (Khakh et al., 2003, Koizumi et al., 2003, Lalo et al., 2014). P2Y 
receptors have been found on astrocytes and interneurons. P2Y receptors on astrocytes 
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induce further ATP release (Anderson et al., 2004), while P2Y receptors on hippocampal 
interneurons increase GABA release (Bowser and Khakh, 2004). It has also been shown 
that astrocyte-derived adenosine can regulate basal synaptic transmission in the 
hippocampus (Panatier and Robitaille, 2016). However, whether this is first released as 
ATP and then broken down to adenosine or just released as adenosine is not yet known. 
Thus, through mGluR5 activation, astrocytes regulate basal synaptic transmission and 
neuronal synchrony (Panatier and Robitaille, 2016).  
1.3.5 Rationale and hypotheses 
As astrocytes can ensheathe up to 140,000 synapses, astrocytes are in a prime 
position to regulate synaptic activity and amplify neuromodulatory actions. It has now 
been established in the hippocampus that astrocytes can respond to a single synaptic event 
through mGluR5 activation and subsequent calcium transients that enable gliotransmitter 
release for modulation of synaptic strength (Nakahara et al., 1997). This makes for an 
incredibly powerful and efficient neuromodulatory network. In addition to this, widely 
distributed serotonin afferents and receptors can exert a vast array of functions on 
synaptic activity that may involve alterations of astrocytic gliotransmitter release in order 
to affect every synapse. Given that P1 and P2 receptors can be activated by astrocytic 
release of ATP and, if necessary, breakdown to adenosine by ectonucleotidases, astrocytes 
may have influence on cortical inhibitory interneuron activity similarly to what has been 
observed in hippocampal circuits (Bowser and Khakh, 2004). Thus, given the unique 
astroglial ability to respond to single events and influence a vast number of surrounding 
synapses, as well as able to extend neuromodulator action to every synapse, we 
hypothesize that: 
1. Astrocytes are involved in the somatosensory cortical paired-pulse 
suppression and 
 
2. Serotonin acts on astrocytes to affect large scale cortical inhibition 
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2.0 Materials and Methods 
2.1 Slice Preparation 
Six to ten week old male C57BL/6 mice were anesthetized with isoflurane and then 
decapitated. The brain was rapidly removed and immediately submersed in ice -cold 
artificial cerebrospinal fluid (aCSF).  A vibrating slice cutter (Leica VT 1200) was used to 
make 350 um thick coronal sections that were taken from the hindlimb somatosensory 
cortex.  Brains were sliced in ice cold aCSF containing the following (in mM): 123 NaCl, 3.5 
KCl, 1.2 NaH2PO4, 2 CaCl2-2H2O, 2 MgSO4-7H2O, 0.4 L-ascorbic acid, 26 NaHCO3, 10 
dextrose, and 2 lactate (pH 7.4 when saturated with 95% O2 and 5% CO2). Slices were cut 
into halves and immediately transferred to a recovery chamber and incubated in aCSF 
saturated with 95% O2 and 5% CO2 for one hour at 30°C and then kept at room 
temperature for an additional hour prior to experimentation. Slices were kept at room 
temperature for up to 6 hours for experimentation. Experiments were performed in 
accordance with the guidelines of the Canadian Council on Animal Care and approved by 
the University of Saskatchewan Committee on Animal Care and Supply. 
2.2 Electrophysiology 
Slices were placed in a perfusion chamber (~2 ml volume) under nylon strings 
attached to a U-shaped platinum frame submerged in and continually perfused with aCSF 
saturated with 95% O2 and 5% CO2 at a rate of ~4 ml/min at room temperature. Slices 
were imaged using a Nikon SMZ1000 stereozoom microscope for placement of recording 
and stimulating electrodes. fEPSP recordings were obtained using a differential amplifier 
(DP311; Warner Instruments) connected to a Digidata 1440A (Molecular Devices) using 
pClamp 10.2 software (Molecular Devices). Signals were captured at 2kHz, high-pass 
filtered at 1 Hz and low pass filtered at 300 Hz. Layer IV/V was stimulated using a paired-
pulse paradigm with paired stimulations 50 ms apart every 20 seconds for the duration of 
each experiment. Recording electrodes were pulled on a vertical Narshige PC-10 two-step 
puller using borosilicate capillaries. Recording electrodes were filled with 0.9% saline and 
positioned in layer II/III of the hindlimb somatosensory cortex using the MP-285 
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manipulator (Sutter, Novata, CA). Stimulation (10-30 uA; 0.6 ms; 0.33 Hz) was applied to 
layer IV/V using a concentric bipolar stimulating electrode (TM88CCINA, WPI, Sarasota, FL, 
USA) via a constant current stimulator (Grass S48 Stimulator) controlled by pClamp 
through the digital output on the Digidata 1440A (Molecular Devices). Only recordings of 
maximal postsynaptic potentials (PSP) greater than 1.2 mV were used in this study 
(conducted at ~60% of max). Serotonin (5-HT; 2mM) was dissolved in normal aCSF and 
delivered to the chamber via bolus application (100 uL) through a syringe connected to PE-
10 tubing (Harvard Apparatus) positioned directly upstream of the recording site through 
a 16 gauge needle. Given the flow rate, volume of the recording chamber (2 ml), and the 
fact that 5-HT had to diffuse into the tissue (~150 um deep), it was estimated that 5-HT 
reached the recording site at less than 50 uM concentration. The effects observed were 
found to be consistent with bath perfusion of 20 uM 5-HT (data not included). Bolus 
injection was used to simulate more closely the phasic physiological release as opposed to 
the slow stable increase in concentration seen with perfusion in the bath, which more 
closely resembles tonic release. Bolus application relates to the rapid release of 
neuromodulators associated with environmental stimuli essential for the modulation of 
executive functions. 
2.3 Drugs  
Drugs purchased from Sigma Aldrich include iodoacetate (IDA), 2-
aminoethoxydiphenylborane (APB), carbenoxolone (CBX), flufenamic acid (FFA), acid blue 
129 (Ab129), bicuculline (BIC), and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX). Suramin 
was purchased from Tocris. Serotonin (5-HT) was purchased from Sigma Aldrich or Abcam 
and ATP was purchased from Sigma Aldrich.  IDA, APB, CBX, FFA, and 5-HT were dissolved 
in normal aCSF before experiments. 5-HT was kept on ice during experiments. MPEP, and 
BIC were dissolved in normal aCSF and kept frozen as stock solutions. Drugs were perfused 
through the slice in the bath perfusate.  
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2.4 Bicuculline experiments 
Baseline recordings were obtained prior to the application of BIC. BIC was then 
perfused in the bath and the resulting effects on fEPSP amplitude were allowed to stabilize. 
BIC in addition to MPEP, IDA, CBX, or Ab129 were then perfused and allowed to stabilize.  
2.5 5-HT experiments 
A baseline recording was acquired prior to the application of 5-HT. 5-HT was then 
applied via bolus injection in the absence of pharmacological agents and its effects were 
allowed to recover to baseline. The slice was then perfused with one of the drugs and 
allowed to stabilize. 5-HT was applied in the presence of the drug and the effect was 
compared to its effects in the absence of the drug. This was repeated for each 
pharmacological agent used in this study. 
2.6 Data Analysis 
The recorded fEPSPs were analyzed using the Clampex program to determine the 
maximum amplitude of pulse 1 and pulse 2. Data were normalized to the average of 10 
baseline recordings. Drug effects were compared in the presence and absence of BIC. Data 
for the drug effects in the absence of BIC were obtained from experiments before the 
application of 5-HT. 5-HT experiments were analyzed by comparing the amplitudes of both 
pulses to pulse 1 during the application of 5-HT in the presence and absence of 
pharmacological agents. 
2.7 Statistics 
Data were expressed as the mean ± standard errors. Statistical significance was 
assessed using paired students t-tests. Significance was determined when p < 0.05. All 
statistical comparisons were performed using Microsoft Excel.  
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3.0 Results 
In order to assess the astrocytic role in cortical inhibition and neuromodulator 
effects we used a paired-pulse paradigm to study evoked inhibition. It has previously been 
established that paired-pulse suppression in the visual (Rozas et al., 2001) and 
somatosensory (Ming et al., 2015) cortex is dependent on GABAA receptors. The first 
evoked field postsynaptic potential (fPSP) represents a summation of both evoked 
excitatory and spontaneous inhibitory/excitatory PSPs (IPSPs/EPSPs). Most of the evoked 
inhibitory PSPs (IPSPs) come at a delay due to the extra synapse involved in excitatory 
recruitment of local interneurons. Thus, due to this delay and the much longer duration of 
IPSPs, the second evoked fPSP represents the summation of evoked EPSPs, evoked long-
lasting IPSPs (from first stimulation) and spontaneous IPSPs/EPSPs. The difference 
between the first and second stimulation is thus, evoked inhibition. By comparing the 
amplitudes of pulse 2 (P2) and pulse 1 (P1) in the paired-pulse ratio, evoked inhibition can 
be assessed (P2/P1). In the absence of pharmacological agents P1 is larger than P2 due to 
recruited inhibition (Fig. 3.1). Various pharmacological agents with and without 
neuromodulators are used to assess the role of astrocytes in cortical inhibition as well as 
neuromodulator-mediated alteration of inhibition.  
3.1 Astrocytic ATP signaling is involved in cortical evoked inhibition  
First, drugs that alter astrocytic function were applied to acutely isolated slices to 
assess the role of astrocytes and ATP on cortical evoked inhibition. MPEP was used to block 
mGluR5 receptors on astrocytes, IDA to inhibit glycolysis to reduce ATP, 2-APB to inhibit 
intracellular rise in astrocytic calcium, CBX and FFA to block ATP release through 
hemichannels, and Ab129 to block P2Y receptors on interneurons (Fig. 3.2). The 
amplitudes of P1, P2 and the P2/P1 were analyzed before and after the application of the 
drugs to assess their effects.  
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Given that mGluR5 glutamate receptors are mainly expressed on astrocytes and 
have been shown to induce astrocyte calcium waves (Nakahara et al., 1997, Panatier et al., 
2011), the glutamate antagonist MPEP (25uM) was applied to block astrocyte activation by 
glutamate. MPEP caused a decrease in the amplitude of P1, but no change in the amplitude 
of P2. The resulting effect on the P2/P1 represents a possible decrease in evoked inhibition 
(Fig. 3.3A).  
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Additional studies provide evidence that astrocytic ATP is involved in synaptic 
inhibition. It has been shown that ATP released from astrocytes in the hippocampus 
(Khakh et al., 2000, Khakh et al., 2003, Bowser and Khakh, 2004, Lalo et al., 2014) as well as 
in the cortex (Lalo et al., 2014) modulates synaptic inhibition. To investigate whether the 
same is true in the somatosensory cortex we used iodoacetate (200uM; IDA) to deplete 
astrocytic ATP levels. Iodoacetate is an inhibitor of the glycolysis enzyme GAPDH and 
hinders astrocyte function. Interfering with glycolysis leads to a drop in ATP levels in 
astrocytes, in turn, weakening astrocyte calcium wave propagation and signaling via 
gliotransmitters (Anderson et al., 2004). As lactate is the main energy source for neurons, 
and astrocytes shuttle lactate to neurons (Tarczyluk et al., 2013), 2mM of lactate was added 
to the aCSF to ensure an energy source for neurons. In a similar trend to MPEP application, 
the application of IDA showed a decrease in the amplitude of P1 and an increase in the 
amplitude of P2. The resulting increase in the ratio suggests a decrease in evoked inhibition 
(Fig. 3.3A).  By interfering with astrocyte glycolysis we were able to alter cortical inhibition. 
If astrocytes are the source of ATP, its release could be causing the effects seen on 
evoked inhibition. We used pharmacological agents to interfere with possible mechanisms 
of ATP release. Gap junction hemichannels have been shown to be expressed in astrocytes 
(Dermietrel et al., 1991) and carbenoxolone (CBX), a hemichannel blocker, has been used 
to block astrocyte gliotransmitter release (Andersson et al., 2007, Brokamp et al., 2012). It 
is possible that ATP is released through hemichannels (Stout et al., 2002). Thus, we 
perfused our slices with CBX (50uM) to assess the effect on this simple inhibitory circuit. In 
the presence of CBX there was no change in the amplitude of P1. However, P2 showed an 
increase (Fig. 3.3A). The increase in P2 amplitude with no change seen in P1 amplitude 
suggests CBX affects evoked inhibition. 
Astrocytic P2Y receptors have been shown to be involved in ATP-induced ATP 
release from astrocytes (Anderson et al., 2004) and the P2Y receptors on interneurons is a 
mechanism by which ATP could mediate inhibition. Therefore, we used the P2Y antagonist 
acid blue 129 (100uM; Ab129) to block ATP receptors on astrocytes and interneurons. In 
the presence of AB129, P1 amplitude decreased, P2 amplitude increased, and there was a 
resulting increase in the P2/P1 (Fig. 3.3A). Ab129 can act indirectly by reducing ATP 
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release from astrocytes thereby reducing the amount available to act on interneuron P2Y 
receptors or it can act directly on P2Y receptors on interneurons to inhibit ATP effects. 
We hypothesized that astrocytes mediate paired-pulse suppression through the 
release of ATP onto interneurons. Interneurons release GABA, which then acts on neurons 
to inhibit synaptic activity. We perfused another set of slices with the GABAA receptor 
antagonist bicuculline (2uM; BIC) to determine if the effects seen with the MPEP, IDA, CBX 
and Ab129 were GABA dependent. There remained changes in P1 amplitude for MPEP, IDA 
and Ab129 as seen in the absence of BIC (Fig. 3.3). In addition, CBX P1 amplitude also 
remained the same, with no difference, as in the absence of BIC (Fig. 3.3). However, all 
significance was lost in the amplitudes of P2 and P2/P1, which are representative of 
evoked inhibition (Fig. 3.3B). All pharmacological agents used reduce ATP and its release 
from astrocytes. As BIC blocks GABAA receptors, and MPEP, IDA, CBX or Ab129 did not 
show any further effect on the P2 amplitude or the P2/P1, these results indicate that 
pharmacological effects on evoked inhibition are dependent on GABAA.  
In addition to the above mentioned pharmacology, we used 2-APB to inhibit the 
intracellular rise in astrocytic calcium, and FFA to block large anion channels including 
hemichannels. As calcium waves help activate and propagate astrocyte signals as well as 
stimulate the release of gliotransmitters. In this study we used the IP3 receptor blocker, 2-
APB (100 uM), to inhibit the release of intracellular calcium to weaken astrocytic calcium 
wave propagation.  With the application of 2-APB, P1 and P2 showed a decrease in 
amplitude but the P2/P1 did not show a significant change (Supplemental Fig. 3.1). Given 
that the application of 2-APB showed no significant change in P2/P1, evoked inhibition was 
not affected. Furthermore, use of the large anion channel blocker flufenamic acid (50 uM; 
FFA) also supports an ion channel mechanism. Although FFA produced a decrease in the 
ratio similar to CBX, FFA only decreased P1 amplitude which is in contrast to CBX only 
increasing P2 amplitude (Supplemental Fig. 3.1).  
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To further investigate the role of ATP in evoked inhibition, the non-selective P2 
receptor antagonist suramin (50uM; SUR) was applied. There was no change in P1, P2 or 
the P2/P1 (Supplemental Fig. 3.2). However, the SUR concentration used may have been 
too low as most studies use a concentration of 100uM. In addition, as ATP is rapidly 
degraded extracellularly into adenosine, we used the selective adenosine A1 receptor 
antagonist DPCPX (300-600nM) to assess its impact on cortical evoked inhibition. DPCPX 
showed no change in P1, P2, or the P2/P1 (Supplemental Fig. 3.2) demonstrating that 
adenosine A1 receptors are not involved in mediating evoked inhibition under basal 
conditions. 
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3.2 5-HT mediated effects on paired-pulse suppression are GABA 
dependent 
Serotonin (5-HT) and norepinephrine (NE) have been shown to alter inhibition in 
the entorhinal cortex (Deng and Lei, 2008, Xiao et al., 2009). As ATP and astrocytes play a 
role in mediating paired-pulse suppression, it is possible that they also mediate 
neuromodulator effects on paired-pulse suppression. We first assessed the response to 5-
HT in the absence of pharmacological agents, using the paired-pulse paradigm. Then we 
applied MPEP, IDA, CBX, Ab129, 2-APB, FFA, SUR, and DPCPX to interfere with astrocytic 
ATP release and determine if ATP plays a role in mediating the response to 5-HT. 
In order to assess if astrocytes and ATP are involved in mediating 5-HT signaling we 
first applied 5-HT in the absence of any drug.  5-HT was applied as a bolus application to 
simulate transient physiological release. This caused P1 amplitude to decrease and P2 
amplitude to increase leading to an increase in the P2/P1 (Fig. 3.4A). These results suggest 
that 5-HT application decreases evoked inhibition.  
If 5-HT decreases inhibition in the cortex, the changes should be sensitive to GABA 
blockade. Thus, we applied 5-HT in the presence of the GABAA antagonist BIC. BIC virtually 
abolishes the response to 5-HT compared to control experiments (Fig. 3.4B).  
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3.3 Astrocytes are involved in 5-HT effects on paired-pulse 
suppression 
Could it be that 5-HT is altering the astrocytic involvement in inhibition? By 
interfering with ATP levels and its release from astrocytes, 5-HT should no longer decrease 
evoked inhibition to the same extent. To test whether 5-HT effects are mediated through 
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ATP and astrocytes, MPEP, IDA, CBX, Ab129, 2-APB, FFA, SUR, and DPCPX were perfused 
through the slice prior to the application of 5-HT. According to our hypothesis, these agents 
should hinder the 5-HT effects on evoked inhibition. In the presence of these 
pharmacological agents, 5-HT showed a decrease in both P1 and P2 compared to controls 
in which P1 amplitude decreased and P2 amplitude increased (Fig. 3.5). The decrease in P1 
amplitude was the same as seen in controls. The inverse response in P2 resulted in a 
dampened increase in the P2/P1 demonstrating that MPEP, IDA, CBX, and Ab129 reduce 
the 5-HT effect on evoked inhibition.  
In addition, 5-HT was applied in the presence of the IP3 antagonist 2-APB 
(Supplemental Fig. 3.3), and another hemichannel gap junction blocker FFA (Supplemental 
Fig. 3.3). In the presence of these drugs, 5-HT produced similar effects as those shown in 
the presence of MPEP, IDA, CBX, and Ab129. P1 amplitude also decreased to the same 
extent as controls and P2 amplitude decreased compared to the increase seen in controls. 
This resulted in a dampened increase in the P2/P1 (Supplemental Fig. 3.3). The FFA results 
are consistent with the results previously shown using CBX.  
3.4 P2 receptors are involved in 5-HT effects on paired-pulse 
suppression 
Given that astrocytic calcium waves can trigger the release of ATP and Ab129 
hindered the 5-HT response, we further investigated the role of ATP in 5-HT signaling 
using the non-selective P2 blocker SUR. Using a non-selective P2 antagonist allowed us to 
assess if ATP was acting through either P2Y and P2X. 5-HT in the presence of SUR resulted 
in no change in the amplitudes of P1, P2 or P2/P1 (Fig. 3.6A). Again, this may have been a 
consequence of the SUR concentration of 50uM instead of 100uM. Future experiments will 
need to be done to verify this possibility.
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In addition, as ATP is degraded rapidly to adenosine by ectonucleotidase enzymes, it 
is possible that adenosine is involved instead of ATP. To test whether ATP is mediating 
5-HT effects and not adenosine, we applied 5-HT in the presence of the adenosine A1 
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receptor blocker DPCPX. This also did not change the 5-HT response effectively ruling out 
adenosine A1 receptors as being involved in 5-HT effects (Fig. 3.6B).  
As interfering with astrocyte function and ATP leads to a change in the effects of 5-
HT on paired-pulse suppression, astrocytes and ATP may be mediating 5-HT effects. In the 
presence of pharmacological agents that hinder astrocyte function and ATP levels, P2 had a 
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similar response to P1 as they both decreased. This resulted in an increase in the P2/P1, 
but it was reduced compared to controls.  As the pharmacological agents used to interfere 
with astrocytic ATP reversed the effects of 5-HT, the mechanism by which 5-HT acts may 
involve the inhibition of ATP release from astrocytes. Thus, we next applied exogenous ATP 
and assessed its effects.   
3.5 Exogenous ATP reduces P2 which is opposite to 5-HT  
To further assess the potential role for ATP in cortical inhibition, we applied 
exogenous ATP to the slices using the same method used to apply 5-HT. When ATP was 
applied both P1 and P2 amplitudes decreased and the P2/P1 increased (Fig. 3.7A). 
Application of ATP resulted in a decrease in P2 amplitude compared to 5-HT that caused its 
increase. Thus, 5-HT seems to be inhibiting ATP release from astrocytes given that ATP 
effects show the inverse effect on P2.  
In addition to applying exogenous ATP, we also used the protease-activated 
receptor 1 (PAR-1) agonist TFLLR. TFLLR has been used to activate astrocytes specifically 
as PAR-1 receptors are thought to be mainly found on astrocytes (Debeir et al., 1997, Han 
et al., 2011, Lalo et al., 2014). TFLLR was perfused through the slice for 3 minutes to allow 
it to reach a constant concentration of 10uM throughout the slice. After 3 minutes of 
perfusion, TFLLR was washed out with normal aCSF to simulate transient action. With the 
application of TFLLR, there was a decrease in P2 amplitude, similar to the effects seen with 
ATP and opposite to the effects of 5-HT (Fig. 3.7B). TFLLR acts on astrocytes to cause a rise 
in calcium (Debeir et al., 1997, Junge et al., 2004) which causes release of gliotransmitters, 
specifically ATP, resulting in an increase in evoked inhibition (Lalo et al., 2014).  
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4.0 General Discussion 
This is one of the first studies to assess the role of astrocytes in cortical inhibition 
and neuromodulation in a more integrated representation using extracellular field 
recordings. We assessed the astrocytic role and 5-HT effects on inhibition using a paired-
pulse paradigm. The pharmacological agents, MPEP, IDA, 2-APB, CBX, FFA, and Ab129, 
were applied to interfere with astrocyte function and ATP release. In order to assess their 
effects, the amplitudes of P1, P2, and P2/P1 were compared before and after the 
application of each agent. MPEP was used to block mGluR5 glutamate receptors on 
astrocytes, IDA to inhibit glycolysis in astrocytes, 2-ABP to block IP3-mediated calcium rise 
in astrocytes, CBX and FFA to block ATP release from hemichannels, and Ab129 to block 
P2Y receptors on interneurons. Application of each agent resulted in an increase in the 
P2/P1 which represents a decrease in inhibition and suggests that astrocytes and ATP are 
involved in cortical inhibition. To verify that all actions were mediated through effects on 
GABAA signaling, we applied the same agents in the presence of the GABAA antagonist BIC. 
In the presence of BIC, all significant changes in the P2/P1 were abolished, supporting the 
notion that astrocytes are involved in GABA-mediated inhibition. As adenosine has also 
been implicated in astrocyte-mediated inhibitory processes, we used the A1 receptor 
antagonist DPCPX to determine if the effects observed were partially mediated by 
adenosine. However, DPCPX showed no change in the P2/P1 ruling out involvement of 
adenosine A1 receptors. Accordingly, we proposed that in response to the first stimulation, 
glutamate is released from the presynaptic neuron and, in addition to acting on receptors 
on the postsynaptic neuron (P1), stimulates astrocytic calcium transients via mGluR5 
glutamate receptors to release ATP to recruit surrounding inhibitory interneurons for 
suppression of the second stimulation (P2; Fig 4.1B). Thus, extracellular field recordings of 
integrated activity enables better understanding, as a single astrocyte is capable of 
regulating activity across multiple synapses. Taken together, we suggest that astrocytes 
modulate inhibition through the release of ATP to widely affect cortical neural function. 
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4.1 Astrocytes detect synaptic activity via mGluR5 
We used the mGluR5 antagonist MPEP to block astrocyte activation in response to 
synaptic glutamate release. When we applied MPEP to our slices there was an increase in 
the paired-pulse ratio indicating a reduction in inhibition. Our results are consistent with 
the study done by Panatier et al. (2011). They demonstrated, with patch clamp, that 
astrocytes regulate basal transmission at hippocampal synapses by detecting glutamate 
release (Fig 4.1) (Panatier et al., 2011). When mGluR5 receptors on astrocytes were 
activated it caused an increase in astrocytic calcium, which in turn, enhanced basal synaptic 
activity (Panatier et al., 2011). Similar to our study, they used the mGluR5 antagonist, 
MPEP, at the concentration of 25 uM (Panatier et al., 2011). MPEP completely abolished 
calcium events in astrocytes thereby reducing synaptic efficacy (Panatier et al., 2011). This 
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suggests that mGluR5 stimulated rises in astrocytic calcium is a critical step in modulating 
synaptic activity. However, although the major metabotropic glutamate receptor expressed 
on astrocytes is mGluR5 (Nakahara et al., 1997), these receptors have also been shown to 
be expressed on neurons and interneurons (Lopez - Bendito et al., 2002, Gereau and 
Swanson, 2008). This could account for the effects of MPEP observed in our study as well 
as Panantier et al. (2011). Blocking mGluR5 receptors would reduce the excitability of 
neurons and/or interneurons, which would, consequently, affect recruitment of inhibition. 
Panatier and colleagues (2011) recorded intracellular EPSCs evoked in pyramidal cells in 
the presence of MPEP (Panatier et al., 2011). MPEP resulted in the failure rate of EPSCs to 
increase, which could be indicative of effects on neurons (Panatier et al., 2011). However, 
they addressed this issue by applying MPEP in the presence of the calcium chelator BAPTA 
in the pipette of a patched astrocyte. When astrocytes were dialyzed with BAPTA, MPEP no 
longer showed an increase in the failure rate of EPSCs demonstrating that its actions are 
mediated through astrocytes and not neurons (Panatier et al., 2011). Thus, the results 
obtained by Panatier et al., using patch clamp, together with our results, using extracellular 
field recordings, demonstrates that astrocytes are recruited into synaptic circuits via 
mGluR5 (Fig 4.1).  
4.2 Presynaptic A2A receptors to modulate glutamate release 
In response to mGluR5 activation, astrocytes release gliotransmitters, including 
purines, to regulate synaptic transmission (Panatier et al., 2011). Given that astrocytes 
have been shown to be activated via mGluR5 (Panatier et al., 2011) and ATP is astrocyte 
currency (Coco et al., 2002, Anderson et al., 2004, Guthrie et al., 1999), we hypothesized 
that, in response to glutamate, astrocytes regulate evoked inhibition through ATP release. 
ATP released from astrocytes would then act on interneurons to modulate GABA release 
(Fig 4.1A). However, this is inconsistent with the Panatier et al. (2011) study as they 
demonstrated that A2A receptors increase pyramidal neuron excitability. They showed 
that in response to glutamate, mGluR5s are activated on astrocytes. Astrocytes then release 
purines which act on A2A adenosine receptors on the presynaptic terminal to increase 
glutamate release (Fig 4.1B) (Panatier et al., 2011). This could account for the effects 
observed in our study. Increasing glutamate release from the presynaptic neuron would 
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increase recruitment of inhibition by stimulating interneurons. By interfering with ATP 
levels and its release, there is less ATP available to be degraded into adenosine by 
ectonucleotidases. This, in turn, would decrease the efficacy of glutamate release, 
consequently decreasing interneuron stimulation. As Panatier et al. (2011) discovered 
using the A2A antagonist SCH 582621 (Panatier et al., 2011), blocking A2A receptors 
mimics the effects, on EPSC failure rates, seen with the mGluR5 antagonist MPEP (Panatier 
et al., 2011). We used the A1 antagonist, DPCPX, to block A1 receptors and assess the role 
of adenosine in cortical inhibition. However, DPCPX produced no change in the paired-
pulse ratio, which lead us to believe that adenosine was not involved. However, we failed to 
consider adenosine A2A receptors. Thus, adenosine could nonetheless be playing a role. In 
addition, our data with SUR showed no effect on P1, P2, or P2/P1, which supports that 
inhibition is regulated through the mechanism described by Panatier et al. (2011). 
However, it could also be a consequence of the concentration we used as we applied 50 uM 
rather than 100 uM, which is the most commonly used concentration (Anderson et al., 
2004, Deng and Lei, 2008, Tang et al., 2015). Ultimately, as Panatier et al. (2011) used patch 
clamp (Panatier et al., 2011) which is representative of a single cell, and we used 
extracellular field recordings which represents a more encompassing physiological 
environment, it is possible that astrocytic purines increase excitability but the overall effect 
is inhibitory. 
4.3 Astrocytic purines are involved in mediating inhibition 
As astrocytes release purines that affect synaptic transmission it is possible that 
ATP and adenosine are both involved in cortical inhibition. We addressed this possibility 
with the use of Ab129, a P2Y antagonist. These data showed a decrease in the paired-pulse 
ratio supporting that ATP mediates inhibition through P2Y receptors. This is in contrast to 
the Panatier et al. (2011) study, as their data support adenosine (Panatier et al., 2011) 
rather than ATP (Fig 4.1). However, it is known that adenosine acts on P1 as opposed to the 
P2 receptors on which ATP acts (Abbracchio et al., 2009). The best known P2 antagonists 
are Evans Blue, reactive blue 2, PPADS and suramin (Zimmermann, 1994). Ab129 is a 
derivative of reactive blue 2 and has been evaluated along with other reactive blue 2 
derivatives for its efficacy and selectivity for P2 receptors (Brown and Brown, 2002). 
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Brown and Brown (2002) found that Ab129 was one of the most potent antagonists 
selective for P2Y receptors (Brown and Brown, 2002). Thus, we are confident that our data 
using Ab129 implicates P2Y receptors. Although the mechanisms described by Panatier et 
al. (2011) (Panatier et al., 2011) implicates adenosine, they failed to consider that ATP acts 
in addition to adenosine in the context of recruiting inhibition. Furthermore, our data are 
consistent with the studies done by Bowser and Khakh (2004) , and Lalo et al. (2014) on 
the involvement of ATP in synaptic transmission (Bowser and Khakh, 2004, Lalo et al., 
2014). We demonstrated that inhibition can be altered by blocking P2Y receptors with 
Ab129. This is consistent with Bowser and Khakh who showed that ATP excites 
interneurons and astrocytes to increase synaptic inhibition (2004) (Bowser and Khakh, 
2004) supporting our hypothesis that astrocytic ATP recruits interneurons (Fig 4.1A). They 
recorded from connected interneuron-pyramidal neuron pairs and used the ATP analog 
ATPyS to prevent its breakdown by ectonucleotidases (Bowser and Khakh, 2004). ATPyS 
caused patched interneurons to become excited and depolarize, subsequently increasing 
inhibition of pyramidal neurons (Bowser and Khakh, 2004). In addition, and consistent 
with our study, they applied P2 receptor agonists to determine which subtype was 
involved. P2Y agonists showed an increase in IPSCs in pyramidal neurons and P2X and 
adenosine agonists did not show any change (Bowser and Khakh, 2004), thereby 
implicating P2Y receptors. Our study, using extracellular field recordings, further supports 
Bowser and Khakh’s (2004) as our results with Ab129 indicated a decrease in paired-pulse 
suppression. In addition, Bowser and Khakh used the P2 receptor antagonist PPADS and 
the P2Y selective antagonist MRS2179 which blocked the effects of P2Y agonists (Bowser 
and Khakh, 2004). This supports our hypothesis that inhibition is mediated through P2Y 
receptors and contests the involvement of P2X and adenosine receptors. Conversely, it has 
been shown that P2Y receptors are present on astrocytes and can induce ATP release 
(Anderson et al., 2004) which could account for our results and Bowser and Khakh’s 
(2004) (Bowser and Khakh, 2004). By applying ATP or its analogs, astrocytic P2Y receptors 
are activated, triggering ATP-induced ATP release (Anderson et al., 2004). Consequently, 
ATP would be available for degradation by ectonucleotidases. Adenosine would then be 
available to act on presynaptic A2A receptors as in the mechanism described by Panatier et 
al. (2011) (Panatier et al., 2011). Due to the action of ATP analogs on astrocytes, they do 
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not necessarily isolate ATP effects as adenosine will still be present. Furthermore, P2Y 
antagonists block P2Y receptors on astrocytes, thereby reducing ATP release, in turn, 
decreasing adenosine. Thus, it is possible that astrocytes mediate inhibition through our 
proposed mechanism, which is consistent with the Bowser and Khakh study (2004), 
involving ATP and P2Y receptors on interneurons and astrocytes (Fig 4.1A) (Bowser and 
Khakh, 2004), through Panatier et al.’s (2011) described mechanism involving adenosine 
and presynaptic A2A receptors (Fig 4.1B) (Panatier et al., 2011), or a combination of both.  
To further validate that purines released from astrocytes are involved in inhibition 
we used IDA to decrease the availability of ATP for release. IDA reduces ATP levels by 
inhibiting GAPDH, an enzyme essential for glycolysis (Schmidt and Dringen, 2009, Nodin et 
al., 2012). By reducing ATP concentration in astrocytes, less ATP is available for release to 
effect inhibition. In the presence of IDA P2/P1 increased, indicative of a decrease in 
inhibition. However, IDA is capable of affecting neurons as well as astrocytes. Lactate is the 
preferred energy substrate by neurons and astrocytes provide lactate to neurons through 
the astrocyte-neuron lactate shuttle (Pellerin et al., 2007). Lactate is essential in order to 
maintain neurotransmission (Pellerin et al., 2007), and interfering with glycolysis reduces 
the lactate available to neurons. Thus, this would appear as an effect on inhibition when in 
fact it is reducing neurotransmission. To counter this, we added 2mM lactate to aCSF in 
order to inhibit astrocyte ATP with IDA but also maintain neuronal function. In addition, 
IDA is a thiol reagent capable of disrupting glutathione metabolism resulting in oxidative 
stress (Liao et al., 2013).  However, Schmidt and Dringen (2009) demonstrated the effects 
of IDA on glycolysis and glutathione in astrocytes and found that IDA is highly effective in 
inhibiting astrocyte glycolysis without substantially compromising glutathione metabolism 
(Schmidt and Dringen, 2009). Another study by Nodin et al. (2012) additionally 
demonstrated that IDA rapidly inhibits GAPDH leading to a resultant decrease in ATP levels 
without increasing oxidative stress (Nodin et al., 2012). Thus, we believe that our use of 
IDA in the presence of lactate allowed us to assess the role of astrocytic ATP without 
affecting neuronal function. The studies done by Panatier et al. (2011) and Bowser and 
Khakh (2004) study support our results with IDA that showed an increase in the P2/P1 
indicative of a reduction in inhibition. However, as we used extracellular field recordings, it 
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remains unclear which mechanisms are responsible but the evidence strongly supports 
that purines are involved in cortical inhibition.  
4.4 The mechanism of astrocytic purine release is uncertain  
In addition to IDA, we used 2-APB which reduces intracellular calcium elevations 
and blocks hemichannels similar to the effects of CBX and FFA. 2-APB is an IP3 receptor 
blocker, which inhibits intracellular calcium release from the endoplasmic reticulum (ER) 
(Peppiatt et al., 2003, Ozaki et al., 2013). When ligands bind to their G-protein receptors it 
induces PLC to form IP3 and DAG from PIP2. IP3 acts to open calcium channels on the ER 
resulting in a rise in intracellular calcium (Berridge, 1993). In addition, DAG and calcium 
activates PKC (Berridge, 1993). When we applied 2-APB, it resulted in a reduction in 
paired-pulse suppression represented by an increase in the P2/P1. Given that many 
neuromodulators use this signaling pathway 2-APB may be affecting activity via the 
inhibition of other neuromodulators. Furthermore, 2-APB is also capable of blocking 
connexin based hemichannels (Bai et al., 2006) and TRP channels (Bencze et al., 2015). 
This causes a further blockade of astrocyte ATP release as astrocytes express hemichannels 
containing connexin 43 (Brokamp et al., 2012) and there is evidence to support that ATP is 
released from astrocyte hemichannels (Stout et al., 2002). Thus, it is possible that our data 
with 2-APB is a result of either calcium blockade in astrocytes, release of ATP or its effects 
on neuromodulator signaling pathways. However, if 2-APB does indeed block 
hemichannels, this supports our CBX and FFA data. We proposed that because inhibition 
was reduced in the presence of CBX and FFA, ATP is released from astrocytes via gap 
junctions. This is consistent with Lalo and colleagues (2014) as they showed that ATP 
modulates inhibition in the cortex (Lalo et al., 2014), albeit through vesicular-mediated 
mechanisms. However, their study demonstrated, using patch clamp and sniffer cell 
approaches in dnSNARE mice, that ATP is released from astrocytes via exocytosis whereas 
we proposed that ATP is released via hemichannels as CBX and FFA increased the P2/P1. 
Thus, it is possible that CBX and FFA are eliciting their effects through a different 
mechanism than what we hypothesized. FFA is a large ion channel modulator (Guinamard 
et al., 2013) that blocks hemichannels and TRP channels (Stridh et al., 2008). In addition it 
blocks the enzyme cyclooxygenase (COX) responsible for the synthesis of inflammatory 
 38 
mediators which affects neurotransmission (Yang, 2009). CBX blocks astrocytic 
hemichannels but has also been shown to interfere with voltage-gated calcium channels 
(Vessey et al., 2004). This reduces synaptic activity, which would explain why we see a 
decrease in inhibition. However, it has also been shown that ATP can be released from 
astrocytic hemichannels and that both mechanisms in combination, (release via 
hemichannels and exocytosis) can facilitate ATP release (Garré et al., 2010, Lalo et al., 2014, 
Wei et al., 2014). In addition, astrocytes use hemichannels to propagate calcium signals 
(Dermietrel et al., 1991). Blocking calcium would further disrupt astrocyte signaling 
resulting in a reduction in ATP release, thus supporting our hypothesis of astrocytic 
involvement in inhibition. However, we cannot rule out that ATP is being released from 
astrocytes via hemichannels, exocytosis, or a combination of both. The fact that Lalo et al. 
(2014) found that astrocytic ATP modulates inhibition (Lalo et al., 2014) in the cortex 
supports our hypothesis that it plays a role in mediating cortical inhibition. 
4.5 ATP effects are GABA dependent 
Since we found that ATP is involved in modulating inhibition, we investigated 
whether it required GABA to elicit its effects. Consistent with the studies done by Bowser 
and Khakh (2004), and Lalo et al. (2014) we found that astrocytic mediation of inhibition 
involved GABA (Bowser and Khakh, 2004, Lalo et al., 2014). When we applied MPEP, IDA, 
CBX, and Ab129 in the presence of the GABAA antagonist BIC we no longer observed an 
effect on inhibition, suggesting that inhibition mediated through astrocytes depends on the 
release of GABA from interneurons. These results are in line with Lalo et al. (2014) as well 
as Bowser and Khakh (2004) as they found that IPSCs in pyramidal neurons mediated by 
ATP were significantly reduced in the presence of BIC (Bowser and Khakh, 2004, Lalo et al., 
2014). This supports our hypothesis that interneurons are excited by ATP to release GABA 
onto their postsynaptic targets (Fig 4.1A). In contrast to our study, Lalo and colleagues 
(2014) found that ATP down-regulated GABAA receptors resulting in a decrease in 
inhibition (Lalo et al., 2014), whereas our data suggest that ATP increases inhibition in the 
cortex. They used P2X knock out mice to show that these effects were mediated through 
ATP and P2X receptors (Lalo et al., 2014). In comparison, our study suggested that ATP is 
acting through P2Y receptors to increase GABA release from interneurons. However, the 
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results obtained in the study done by Lalo et al. (2014) were acquired using patched 
pyramidal neurons, and ATP actions on interneurons were not accounted for. Thus, ATP 
release from astrocytes could be acting on pyramidal neurons through P2X receptors and 
on interneurons via P2Y receptors. This may explain the large effect we observe on the first 
stimulation with exogenous ATP administration. In addition, as we used extracellular 
recordings instead of patch clamp recordings, it is possible that ATP excites pyramidal 
neurons but the overall effect on the neural circuitry remains inhibitory through 
facilitation of GABA release from interneurons.  
4.5.1 GABAA and not GABAB receptors are responsible for the observed results 
It is possible that GABA acts on GABAA and GABAB receptors to mediate effects on 
inhibition (Rozas et al., 2001). Carlos Rozas and colleagues (2001) have demonstrated that 
GABA, does indeed, act through GABAB receptors but its response peaks considerably later 
than GABAA (Rozas et al., 2001). They assessed the effects of GABAA and GABAB on paired-
pulse suppression by using a range of interstimulus intervals, the GABAA antagonist 
picrotoxin, and the GABAB antagonist saclofen (Rozas et al., 2001). They found that 
picrotoxin reduced paired-pulse suppression at shorter intervals including 20, 40 and 80 
ms intervals between P1 and P2, and that saclofen reduced paired-pulse suppression at 
longer intervals including 80, 160, and 320 ms intervals between pulses (Rozas et al., 
2001). We used an interstimulus interval of 50 ms which is too short for GABAB to have an 
effect, and therefore did not evaluate a GABAB antagonist. In contrast to Rozas et al. (2001), 
we did not observe an effect on the P2/P1 in the presence of BIC. However, it was able to 
effectively block the effects of MPEP, IDA, CBX, and Ab129. In line with Rozas et al. (2001) 
we applied a sub-saturating concentration of GABAA antagonist to prevent excessive 
excitation. The fact that BIC had no effect on the P2/P1 may  have been a result of adding 
lactate to our aCSF. We added lactate in order to maintain neurotransmission in the 
presence of the agents used in our study. Studies have shown that lactate seems to be 
involved in maintaining GABAergic receptor activity (Laschet et al., 2004), synaptic vesicle 
cycling (Morgenthaler et al., 2006), and enhancing the accumulation of GABA vesicles 
(Tarasenko et al., 2006). Rozas et al. (2001) did not use lactate in their solutions which 
would account for why they observed a decrease in paired-pulse suppression in the 
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presence of a GABAA antagonist and we did not. In addition, in prior studies without lactate 
we also observed an effect on paired-pulse suppression (Ming et al., 2015) similar to that 
shown by Rozas et al. (2001) (Rozas et al., 2001). Interestingly, Rozas et al. (2001) also 
showed that GABAergic inhibition increases in the presence of the GABAA modulator 
diazepam (Rozas et al., 2001). The study done by Rozas et al. (2001) in addition to the 
studies done by Bowser and Khakh (2004), and Lalo et al. (2014) support our results that 
astrocytic mediation of inhibition involved GABAA signaling pathways (Rozas et al., 2001, 
Bowser and Khakh, 2004, Lalo et al., 2014).  
4.6 Astrocytes release purines to modulate GABAergic inhibition 
In line with previous studies (Rozas et al., 2001, Bowser and Khakh, 2004, Panatier 
et al., 2011, Lalo et al., 2014), our results suggest astrocytic purines are involved in 
inhibition and that their effects are dependent on GABA. We proposed that astrocytes sense 
synaptic activity through mGluR5 receptors, resulting in an intracellular rise in calcium and 
ATP release. This was consistent with Panatier et al. (2011). Further, we suggested that 
ATP would then act on interneurons to enhance GABAergic output onto pyramidal neurons 
to increase inhibition. This is in line with the study done by Bowser and Khakh (2004) 
(Bowser and Khakh, 2004), however, there are multiple ways in which inhibition is 
mediated (Fig 4.1). These mechanisms include adenosine A2A receptors on presynaptic 
terminals (Fig 4.1B) as described by Panatier et al.(2011) (Panatier et al., 2011), P2Y 
receptors on interneurons (Fig 4.1A) as described by Bowser and Khakh (2004) , and P2X 
receptors as described by Lalo et al. (2014) (Bowser and Khakh, 2004, Panatier et al., 2011, 
Lalo et al., 2014). Thus, it is clear that astrocytic ATP and its metabolites play a role in 
mediating inhibition but multiple mechanisms are involved. 
4.7 5-HT effects on inhibition 
5-HT effects were compared in the presence and absence of the same 
pharmacological agents. In the absence of pharmacological agents, application of 5-HT 
caused a decrease in P1, an increase in P2, and an increase in P2/P1 that is completely 
abolished in the presence of BIC demonstrating that 5-HT mediates its actions exclusively 
via inhibition. Thus, we investigated whether 5-HT reduced inhibition by acting on 
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astrocytes. We then applied ATP and TFLLR in the absence of pharmacological agents to 
compare their effects to 5-HT effects. ATP application produced a decrease in both P1 and 
P2, and TFLLR generated similar results. This supports that ATP is being released from 
astrocytes to affect inhibition as TFLLR selectively activates astrocytic PAR-1 receptors to 
facilitate gliotransmitter release (Panatier et al., 2011). ATP and TFLLR showed a decrease 
in P2 as opposed to an increase, opposite to the effects observed with 5-HT. This suggests 
that 5-HT is acting on astrocytes to inhibit ATP release, in turn causing a decrease in 
evoked inhibition. 
4.7.1 5-HT1A and 5-HT2A can alter inhibition 
Our results are consistent with a study done by Deng and Lei (2008) (Deng and Lei, 
2008). They found that 5-HT increased spontaneous IPSCs and reduces evoked IPSCs (Deng 
and Lei, 2008) which accounts for our observations in which 5-HT initially decreased the 
amplitude of P1 but increased the amplitude of P2. In addition to affecting inhibition, Deng 
et al. (2007) demonstrate that 5-HT directly inhibits pyramidal neuron excitation through 
5-HT1A receptors (Deng et al., 2007). Deng and Lei (2008) also found that 5-HT2A 
receptors are responsible for increasing the excitability of interneurons (Deng and Lei, 
2008) which increased spontaneous inhibition (Fig 4.1C). However, they found that 5-HT 
reduced evoked IPSCs which was explained in part by the fact that 5-HT decreased action 
potentials through the inactivation of interneuron sodium channels (Deng and Lei, 2008). 
This is consistent with our hypothesis as we proposed that interneurons regulate 5 -HT 
effects on inhibition through GABAA receptors which we confirmed using BIC. In line with 
Deng and Lei (2008), in which they determined the effects of 5-HT on IPSCs to be sensitive 
to BIC (Deng and Lei, 2008), our study showed that 5-HT no longer produced an increase in 
the P2/P1 and P2 amplitude in the presence of BIC. However, we believe that in addition, 5 -
HT alters astrocytic ATP release, in turn, effecting evoked inhibition.  
4.7.2 Astrocytic purines are involved in 5-HT effects 
We found that by interfering with astrocytes we were able to reduce the effects of 5 -
HT on inhibition. As previously discussed, our data suggests that astrocytic release of ATP 
increases inhibition in the cortex by exciting interneurons and increasing GABA release. 
 42 
Therefore, we alluded that 5-HT is inhibiting ATP release to cause a decrease in inhibition. 
Our results are consistent with the study done by Panatier et al. (2011) as they showed that 
inhibition of astrocytic activity can reduce presynaptic excitability  leading to reduced 
excitability (Panatier et al., 2011) which includes interneurons (Fig 4.1B). In addition, 
Bowser and Khakh (2004) showed that astrocytic ATP mediates inhibition through 
interneurons (Fig 4.1A) (Bowser and Khakh, 2004). In the Deng and Lei (2008) study they 
did not consider a role for astrocytes (Fig 4.1C) (Deng and Lei, 2008). They used SUR as a 
G-protein inhibitor, but it is also known to be a non-selective P2 antagonist (Deng and Lei, 
2008), which implicates ATP in 5-HT effects. Thus, as we observed a decrease in inhibition 
when 5-HT was applied which was reversed in the presence of ATP limiting agents, lead us 
to the conclusion that 5-HT is inhibiting ATP resulting in decreased inhibition.  
4.8 ATP effects on cortical inhibition 
 We applied ATP in order to compare its effects to 5-HT and assess whether 5-HT 
inhibits its release from astrocytes to affect inhibition. When ATP was applied we observed 
a decrease in P2 amplitude in comparison to 5-HT application where we observed an 
increase.  Thus, we suggested that 5-HT is blocking the release of ATP would result in the 
inverse effect. To test whether ATP was being released from astrocytes we applied TFLLR 
to selectively activate astrocytes through the PAR-1 receptor. In the presence of TFLLR we 
observed similar effects as we had with the application of ATP, supporting that ATP is 
released from astrocytes. This is in line with the study done by Lalo et al. (2014) as they 
found that application of TFLLR elevated calcium in astrocytes and elicited currents in ATP 
sensitive sniffer cells (Lalo et al., 2014). Thus, it is evident that astrocytes release ATP in 
response to TFLLR (Lalo et al., 2014). Therefore, it is possible that 5-HT decreases 
inhibition through inhibition of astrocytic ATP. However, we were not able to block the 
effects of ATP, when applied exogenously, with Ab129, PPADS, or SUR (data not included), 
thus it is unclear how exogenous ATP is affecting our slices. This could be a result of the 
technique we used as we used extracellular field recordings compared to patch clamp 
studies (Bowser and Khakh, 2004, Lalo et al., 2014). In these studies, they were able to 
observe currents in single cells induced by the application of ATP or its analogs and were 
able to block these currents with ATP antagonists. Through the use of specific agonists and 
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antagonists Bowser and Khakh (2004) deduced that ATP excites interneurons through P2Y 
receptors (Bowser and Khakh, 2004). In contrast, Lalo et el. (2014) deduced from their 
data that ATP effects were mediated through P2X receptors (Lalo et al., 2014). However, 
we were unable to inhibit ATP effects which may be a consequence of the fact that our 
recordings included more complex circuitry rather than the single cell recordings used in 
the studies done by Bowser and Khakh (2004), and Lalo et al. (2014) (Bowser and Khakh, 
2004, Lalo et al., 2014). 
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5.0 Conclusion 
 Astrocytes are involved in cortical inhibition 
 Astrocytic purine release plays a role in mediating cortical inhibition 
 5-HT affects astrocytes to alter inhibition 
 ATP is altered by 5-HT to affect inhibition  
We hypothesized that inhibition in the cortex is mediated through astrocytic release 
of ATP and that it is altered by neuromodulators such as serotonin. Upon critical 
examination of our data and the evidence presented by others (Bowser and Khakh, 2004, 
Deng and Lei, 2008, Panatier et al., 2011, Lalo et al., 2014), it is evident that astrocytic ATP 
plays a role in mediating inhibition in cortical networks. In addition, it seems that 5-HT acts 
on astrocytes to alter ATP release, thereby affecting inhibition. However, the mechanism 
remains unclear. The study done by Bowser and Khakh (2004) supports our idea that 
astrocytes release ATP to excite interneurons for an overall inhibitory effect (Bowser and 
Khakh, 2004), but Panatier et al. (2011) suggests that adenosine acts to increase the 
efficacy of presynaptic release of glutamate (Panatier et al., 2011). Moreover, Lalo, et al. 
(2014) suggest that ATP release from astrocytes enhances excitability of pyramidal 
neurons (Lalo et al., 2014). Thus, it is evident that astrocytes are involved but the 
mechanism of how ATP or adenosine is acting to induce these effects remains unclear. 
However, our results are consistent with these studies as the effects on inhibition as well as 
5-HT effects described are mediated through interneuron release of GABA. Furthermore, 
we found that 5-HT may be acting to alter these mechanisms and change inhibition in the 
cortex. Based on our data and the evidence presented by Deng and Lei (Deng and Lei, 
2008), we suggest that 5-HT is acting to inhibit ATP release from astrocytes. They 
suggested that there is an initial increase in inhibition mediated via 5-HT2A receptors on 
interneurons (Deng and Lei, 2008), and a decrease in excitation mediated through 5-HT1A 
receptors on the presynaptic terminal (Deng et al., 2007). They found that spontaneous 
inhibition was increased and evoked inhibition was decreased with the application of 5-HT. 
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We showed that by interfering with astrocytes with the application of MPEP, IDA, 2-APB, 
CBX, FFA, and Ab129, 5-HT effects on evoked inhibition were reduced. Thus, we maintain 
that astrocytes are involved in mediating inhibition in the cortex and 5-HT can alter it. 
However, the mechanisms remain unclear. The use of extracellular field recordings 
represents a more physiological environment which gives us a better understanding of 
overall activity. However, it makes it difficult to isolate specific mechanisms at play as it 
includes all aspects that may be interacting to modulate inhibition. The studies discussed 
use whole cell patch clamp techniques that provide a more reductionist approach allowing 
them to isolate such mechanisms, but this is not necessarily representative of what is 
occurring overall. Therefore, it is possible that a combination of the proposed mechanisms 
described is eliciting effects on inhibition in cortical networks. More research is needed to 
determine the specifics of astrocyte influence on synaptic inhibition and how 5-HT affects 
astrocytes to modify this. 
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6.0 Future Directions 
As there are many possible mechanisms by which astrocytes may mediate inhibition in 
cortical networks, future research is needed in order to determine the combinations of 
mechanisms that are involved and how they interact to elicit the effects observed  on 
inhibition. Panatier et al. (2011) suggested that inhibition is mediated through the release 
of adenosine from astrocytes to act on presynaptic terminals affecting the efficacy of 
glutamate release (Panatier et al., 2011). In order to determine if this is consistent in our 
study we have plans to repeat experiments in the presence of the A2A blocker SCH 582621 
and examine its effects on paired-pulse suppression and the 5-HT response.  However, in 
line with our hypothesis, Bowser and Khakh (2004) suggested that it is through astrocytic 
release of ATP that inhibition is mediated (Bowser and Khakh, 2004). In order to test this 
in the more complex extracellular field recordings that are more representative of 
physiological conditions, it would be interesting to apply an ectonucleotidase inhibitor 
such as apyrase. Apyrase prevents the degradation of both exogenous and endogenous ATP 
and would allow us to observe the effects of elevated ATP and rule out the action of its 
metabolites. 
Extracellular field recordings that include all activity in the area surrounding the 
recording pipette (~100-200 um diameter) enable an integrated understanding of the 
overall effects but made it difficult to conclusively determine the mechanism by which ATP 
is involved in cortical inhibition and the 5-HT effects. Thus, it would be useful to perform 
further studies using patch clamp techniques to measure inhibitory synaptic events 
directly. Patch clamp provides many options to study inhibition in the cortex, including but 
not limited to, the direct measure of inhibitory and excitatory currents in pyramidal 
neurons and interneurons in the presence and absence of pharmacological agents and 
neuromodulators. We could then examine the changes in currents in specific cells in 
response to pharmacological agents and 5-HT using a more reductionist model such as in 
the studies done by Deng and Lei (2008),  Panatier et al. (2011), Bowser and Khakh (2004), 
and Lalo et al. (2014) (Bowser and Khakh, 2004, Deng and Lei, 2008, Panatier et al., 2011, 
Lalo et al., 2014). Patch clamp studies would be useful in determining the specific receptors 
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and mechanisms involved in cortical inhibition and 5-HT effects on neurons, interneurons, 
and astrocytes.  This would allow us to compare results using patch clamp to results using 
extracellular field recordings in order to determine specific mechanisms and how they 
interact to result in the overall effects. 
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